Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Alzheimer's Drug Exelon Captures 25% Of New Rxs In U.S.

Executive Summary

Novartis is finding room for new Rx growth in the Alzheimer's treatment category, where Exelon has nearly doubled its share of new Rxs in the past two months.

You may also be interested in...



Novartis To Launch Anti-Diabetic Starlix In February With Firm's 4,000 Reps

Novartis plans to launch its first anti-diabetic, the type 2 diabetes therapy Starlix, in February using its 4,000 U.S. sales reps. Novartis reps target mostly primary-care physicians and will be trained in the anti-diabetic area.

Novartis To Launch Anti-Diabetic Starlix In February With Firm's 4,000 Reps

Novartis plans to launch its first anti-diabetic, the type 2 diabetes therapy Starlix, in February using its 4,000 U.S. sales reps. Novartis reps target mostly primary-care physicians and will be trained in the anti-diabetic area.

Eisai/Janssen Aciphex Sales Closing In On $250 Mil. 13 Months After Launch

Janssen/Eisai's proton pump inhibitor Aciphex (rabeprazole) is closing in on $250 mil. in sales after 13 months on the market, Eisai U.S. Chairman Soichi Matsuno indicated Oct. 3 at a UBS Warburg Global Life Sciences Conference in New York City.

Related Content

UsernamePublicRestriction

Register

PS036752

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel